Peptides Mentioned by Brigham Buhler on Joe Rogan Experience #2079
This conversation focused on FDA policy, compounding pharmacies and Buhler's criticism of how peptide access was being regulated. It was not a catalogue of peptide stacks. The transcript supports one named peptide discussion: BPC-157.
#2079 — Brigham Buhler
Guest: Brigham Buhler · Released December 27, 2023
Open the official podcast listingHow this article was verified
Apple Podcasts confirms episode #2079, Brigham Buhler as the guest, and the December 27, 2023 release date. In the official PowerfulJRE episode and its public transcript, BPC-157 is the peptide discussed by name. This page is limited to that episode and does not carry over claims from Buhler's other appearances.
Compounds discussed in this episode
Speaker claims below are paraphrases, not endorsements or quotations. Scientific context is separated from the speaker's experience or opinion.
01BPC-157
What the speaker said
Buhler used BPC-157 as his example while arguing that the FDA's Category 2 treatment chilled physician prescribing. He claimed reported adverse events were tied almost exclusively to unregulated, contaminated black-market material and argued that regulated compounding would reduce that risk. Rogan agreed with the broader policy critique. These are Buhler's regulatory and safety assertions; the episode did not establish them with a controlled safety dataset.
Scientific Context
BPC-157 has extensive animal literature but no established FDA-approved therapeutic use. A lack of a large adverse-event signal is not proof of safety when exposure, product identity and reporting are poorly measured. Contamination is a genuine additional risk, but even a chemically pure research material would not resolve unknown pharmacology, long-term effects or efficacy.
Where to buy for laboratory research
BPC-157 at Base Peptides — verified exact-name product page. This editorial listing is not a guest endorsement and is not a recommendation for human use.
Sources and limitations
- Apple Podcasts: JRE #2079 — authoritative episode listing and release date
- Official PowerfulJRE upload — primary audiovisual source and public transcript
- FDA: bulk substances that may present significant safety risks — primary regulatory context; inclusion decisions are not equivalent to an efficacy assessment
- PubMed review of BPC-157 — peer-reviewed overview showing why animal findings should not be presented as proven human benefit
Research and educational use only. Most compounds discussed here are not FDA-approved to treat injury, improve performance, or extend lifespan. Laboratory supplier links are editorial references only. Nothing here is medical advice, a dosing guide, or a recommendation for human use.